Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  OTC Bulletin Board - Other OTC  >  Sorrento Therapeutics Inc    

News SummaryMost relevantAll newsSector news 

Sorrento Therapeutics Inc : Sorrento Therapeutics Acquires Clinical Stage Drug Candidate for Treatment of Chronic Pain

share with twitter share with LinkedIn share with facebook
share via e-mail
10/11/2013 | 01:16am CEST

SAN DIEGO, Oct. 10, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC QB: SRNE; Sorrento) announced today that it has acquired Sherrington Pharmaceuticals, Inc. (Sherrington), a privately-held company focused on the development of a chronic pain treatment for end-stage cancer patients and other severe pain indications.

Sherrington's drug candidate, known as Resiniferatoxin, is a non-opiate, ultra potent and selective agonist of the TRPV-1 receptor. A single injection of the compound is expected to permanently block the transmission of pain signals without impairing the mental or physical faculties of the patient, common side effects of opiate treatment. Resiniferatoxin was recently highlighted in the July 2013 issue of Scientific American(1). Resiniferatoxin is currently in an investigator-sponsored Phase 1/2 clinical trial at the National Institutes of Health (NIH) under a company sponsored Collaborative Research and Development Agreement (CRADA). Sorrento plans to initiate additional clinical studies to rapidly advance the drug.

"Sorrento's drug development pipeline now includes an additional clinical stage program to go along with its late stage program Cynviloq(TM) and robust pipeline of fully human therapeutic antibodies," said Henry Ji, Ph.D., President and Chief Executive Officer of Sorrento. "Resiniferatoxin is a great fit with our mission to treat cancer patients with targeted and selective treatments. End-stage cancer pain is a particularly high unmet medical need and the early data with Resiniferatoxin are very encouraging."

About Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc. is a publicly-traded, development-stage biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs in the Unites States, Europe and additional international markets. Sorrento's therapeutic focus is oncology, but it is also developing therapeutic products for inflammation, metabolic, and infectious diseases. Sorrento's proprietary G-MAB® fully-human antibody library platform was designed to facilitate the rapid identification and isolation of highly specific antibody therapeutics. In addition, Sorrento is developing proprietary ADCs as well as AfDCs combining its G-MAB® antibodies with anti-tumor agents.

More information is available at www.sorrentotherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Words such as "assumes," "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements. Forward-looking statements include statements about the preclinical and clinical development of Sorrento's human antibody therapeutics. All such forward-looking statements are based on Sorrento's current beliefs and expectations, and should not be regarded as a representation by Sorrento that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Sorrento's businesses; the potential for approval and commercial success of Cynviloq or for further development of Resiniferatoxin; the scope and validity of patent protection for Sorrento's platform technologies, and the risk that the development or commercialization of product candidates may infringe the intellectual property rights of others; the potential that Sorrento may require substantial additional funding in order to obtain regulatory approval for and commercialize Sorrento's proprietary G-MAB® fully-human antibody library platform technologies or product candidates; and additional risks set forth in Sorrento's filings with the Securities and Exchange Commission. These forward-looking statements represent Sorrento Therapeutics' judgment as of the date of this release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Sorrento undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

(1) http://www.scientificamerican.com/article.cfm?id=prickly-painkiller

SOURCE Sorrento Therapeutics, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
10/06 SORRENTO THERAPEUTICS : ARK Animal Health, a Subsidiary of Sorrento Therapeutics..
09/22 SORRENTO THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and..
09/13 SORRENTO THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other ..
09/07 SORRENTO THERAPEUTICS, INC. : Changes in Registrant's Certifying Accountant, Fin..
08/23 SORRENTO THERAPEUTICS INC : Levi & Korsinsky, LLP Announces an Investigation Inv..
08/18 SORRENTO THERAPEUTICS : Scintilla Pharmaceuticals, a Subsidiary of Sorrento Ther..
08/17 SORRENTO THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other ..
08/15 SORRENTO THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (f..
08/12 SORRENTO THERAPEUTICS : SRNE) Finalizes Private Placements worth $150 Million
08/08 SORRENTO THERAPEUTICS : Management's Discussion and Analysis of Financial Condit..
More news
Sector news : Bio Therapeutic Drugs
10/21DJU.S. HOT STOCKS : Hot Stocks to Watch
10/20DJALKERMES : Shares Surge
10/20 ACTELION : raises guidance for third time this year on strong PAH sales
10/18 Pfizer to start shipping biosimilar version of J&J's Remicade in November
10/17DJPfizer Plans to Launch Remicade Biosimilar in November
More sector news : Bio Therapeutic Drugs